New fNIR Technology Sheds Light on Brain Activity with Powerful Imagers for Real-world Situations
Systems offer comfort and mobility to measure human subjects in the lab, at home, or in the real world
GOLETA, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- BIOPAC Systems, Inc., the global distributor for fNIR Devices, announced the availability of its newest generation of functional near infrared optical imaging (fNIR) systems. The new high-density imaging systems provide in-lab or real-world cognitive function assessments for physiology researchers looking to understand brain activity without all the expense of fMRI.
The extra-lightweight sensor fits comfortably on the forehead where it monitors relative changes in oxy or deoxy hemoglobin as a proxy for the brain activity in the pre-frontal cortex. Subjects can be examined in laboratory settings or they can be active in their natural environment with the new mobile fNIR system.
The new NIRS systems offer three powerful imagers. The fNIR 2000C is a stationary unit that collects data from up to 18 optodes. The fNIR 2000M is a wireless and mobile imager that collects data from up to 18 optodes and can be used while subjects are performing tasks in the lab or in the real world. The fNIR 2000S is a 54-optode capable imager with advanced features for recording up to three subjects simultaneously.
A new through-the-hair sensor will allow researchers to assess other areas of the brain such as motor and visual cortices. Adding in different parts of the brain increases understanding of brain activity without the complications of fMRI.
All systems include fNIRSoft and COBI software for data collection and analysis. Data can be synchronized with and imported into AcqKnowledge Software for a complete understanding of physiological response, including EEG, EDA, ECG, BP, and other important physiology signals.
“Experimental design can be more sophisticated with this mobile technology. It gives researchers the opportunity to collect data from subjects as they live their lives.” said Frazer Findlay, BIOPAC’s CEO. “Mobile imaging can add value to any study but is especially important when subjects are children or families, as they can be in a familiar or comfortable environment, yielding better results.”
“When designing and manufacturing fNIR Devices, we decided not to weigh down the subject’s head with a battery and extra electronics. As a result, our imagers, including our wireless imager, measure the brain’s hemodynamic response with minimal weight and maximum comfort.” said Davood Tashayyod, fNIR Devices CEO. “fNIR Devices systems are very easy to set up and very comfortable for the subject. A comfortable subject produces better quality data and can participate in short- and long-term studies.”
fNIR and NIR imaging are citied in over 132,000 publications. NIR applications include Brain Computer Interface, Human Performance Assessment, Neurorehabilitation, Depth of Anesthesia Monitoring, and more. fNIR technology can also be used to understand blood oxygenation of muscles.
Contact BIOPAC for more information about using fNIR technology for measuring mobile subjects in real-world situations, stationary subjects in a lab, or when teaching students in an educational environment.
About BIOPAC Systems
BIOPAC was founded in 1985 and is recognized around the world as a premier choice for life science hardware and software. Worldwide, over 99% of the top 100 universities and Global Fortune 500 companies rely on BIOPAC systems for their life science research and teaching system needs. BIOPAC makes high-quality scientific tools for physiology measurement and interpretation. BIOPAC solutions range from educational solutions to cutting-edge devices for use in lab, real world, and virtual reality research environments. For more information on BIOPAC products, visit www.biopac.com.
About fNIR Devices
Founded in 2009, fNIR Devices, LLC, is the premier supplier of Continuous Wave Functional Near Infrared (fNIR) Spectroscopy imaging systems for research and other non-clinical applications. fNIR Devices provide physiology researchers with robust and meticulously crafted systems for monitoring the brain’s hemodynamics, thereby understanding the subject’s cognitive state in both lab and natural environments.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ea24834a-8a45-4d6c-a5d8-46271fa5f249
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
WillScot to Participate at the Barclays Industrial Select Conference16.1.2019 21:00 | Pressemelding
BALTIMORE, Jan. 16, 2019 (GLOBE NEWSWIRE) -- WillScot Corporation (“WillScot”)(NASDAQ: WSC), the specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that Brad Soultz, President and Chief Executive Officer, and Tim Boswell, Chief Financial Officer, will present at the Barclays Industrial Select Conference at the Loews Miami Beach Hotel in Miami, Florida, on Wednesday, Feb. 20, 2019. The presentation will take place at 10:20 a.m. EST. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the WillScot family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol “WSC.” WillScot is the specialty rental services market leader providing innovative modular space and portable storage solutions across North America. It is the modular space supplier of choice for t
CCI has been retained by Waterloo Brewing to obtain Cannabis Licence16.1.2019 16:00 | Pressemelding
TORONTO, Jan. 16, 2019 (GLOBE NEWSWIRE) -- Cannabis Compliance Inc., (CCI) of Toronto, Ontario is pleased to announce they have partnered with Waterloo Brewing to help them obtain their Research and standard Processing Licence to develop cannabis-infused beverages. “CCI is working with Waterloo Brewing on the early stages of the application process and we are confident that we will help them achieve their desired licenses in time to be an active player in this growing sector of the cannabis industry”, said Brian Wagner, CEO and Founder, Cannabis Compliance Inc. “We are here to guide our clients through the early stages of the licensing process and for the many Health Canada requirements thereafter.” CCI offers end to end business solutions for cannabis companies large and small. Our team brings with them years of experience in the quality, regulatory, security and cultivation sectors, and supports manufacturers and retailers through regulatory challenges. As the world’s largest and mos
Aryaka Announces Expansion of Senior Leadership Team with New Chief Revenue Officer, Chief Transformation Officer and Chief Marketing Officer16.1.2019 15:00 | Pressemelding
Karen Freitag, Michelle Owczarzak, & Shashi Kiran join Aryaka to address significant growth and assist global enterprises in adopting managed connectivity as-a-service SAN MATEO, Calif., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Aryaka®, announced today the appointment of several new executive hires to the company’s leadership team, including Karen Freitag (Chief Revenue Officer), Michelle Owczarzak (Chief Transformation Officer), and Shashi Kiran (Chief Marketing Officer). “Connectivity is the lifeblood of the global enterprise and Aryaka is the industry benchmark for secure managed connectivity worldwide. We are excited to have experienced industry veterans join our robust executive leadership team and continue to help build upon the immense success and growth that Aryaka has seen in recent years,” said Matt Carter, CEO of Aryaka. “As our customers expand globally, embrace SD-WAN, or move to the cloud, we’re becoming the de facto choice for their needs to make this happen better, faster, che
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors16.1.2019 07:00 | Pressemelding
Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors LAUSANNE, Switzerland, Jan. 16, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-601 in patients with selected solid tumors that are locally advanced or metastatic. ADCT-601 is an ADC composed of a humanized monoclonal antibody against human AXL, conjugated using GlycoConnect™ site specific conjugation technology to a pyrrolobenzodiazepine (PBD) dimer toxin. In preclinical studies, ADCT-601 demonstrated potent and specific in vitro and in vivo anti-tumor activity in multiple cancer-derived models with different levels of AXL expression, and was stable and well tolerated
GSA Europe’s Managing Director Elected Co-lead of CEN’s TC456 Committee15.1.2019 21:12 | Pressemelding
SAN GWANN, Malta, Jan. 15, 2019 (GLOBE NEWSWIRE) -- GSA Europe’s Managing Director Mark Pace has been elected by the Comité Européen de Normalisation (CEN) to lead the creation of a European Union online gaming reporting standard. CEN has established Technical Committee 456 to create this standard in support of online gambling supervision. GSA Europe joined Technical Committee 456 as a Liaison Organization in 2017. The Technical Committee’s mandate from the European Commission is directly aligned with work that GSA Europe has already started, namely, to create a single standard set of data elements and single standard way in which data is provided by online gambling providers to EU Member State regulatory authorities. In addition to joining and now leading the Technical Committee’s work, GSA Europe also donated their draft Regulatory Data Set and Regulatory Reporting Interface to CEN seeking to help jump-start the Committee’s work. “Joining CEN’s TC456 as a Liaison Organization, and no
Orion Biotechnology Reports Positive Results for Colorectal Cancer in Preclinical Study15.1.2019 15:00 | Pressemelding
OTTAWA, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced preclinical data produced in collaboration with Charles River Laboratories, evaluating the efficacy of OB-002O (5P12-RANTES) in colorectal cancer. BALB/c mice were inoculated subcutaneously with the CT-26 colorectal cancer cell line. Three days after inoculation intraperitoneal treatment was started with OB-002O, a murine anti-PD-1 antibody, OB-002 + anti-PD-1, or saline placebo. Treatment was given daily or every third day. Treatment with OB-0020 alone led to statistically significant delayed tumor growth at multiple time-points. An even more profound effect on the decrease in mean tumor volume was observed in combination cohort where animals received both, OB-0020 and the anti-PD-1 antibody (p>0.05). “There is growing awareness of the role of CCR5 antagonism as an important component of cancer immunotherapy. OB-002O is an extremely potent CCR5 antagonist